TimesSquare Capital Management LLC Invests $22.04 Million in Mirum Pharmaceuticals, Inc. $MIRM

TimesSquare Capital Management LLC acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the third quarter, according to its most recent disclosure with the SEC. The fund acquired 300,649 shares of the company’s stock, valued at approximately $22,041,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MIRM. Caprock Group LLC bought a new stake in Mirum Pharmaceuticals during the 3rd quarter worth approximately $353,000. Baader Bank Aktiengesellschaft purchased a new stake in shares of Mirum Pharmaceuticals in the third quarter worth $503,000. Essex Investment Management Co. LLC raised its position in shares of Mirum Pharmaceuticals by 0.6% during the 3rd quarter. Essex Investment Management Co. LLC now owns 113,458 shares of the company’s stock valued at $8,318,000 after purchasing an additional 727 shares during the period. Bryce Point Capital LLC purchased a new position in shares of Mirum Pharmaceuticals during the 3rd quarter valued at $463,000. Finally, Candriam S.C.A. lifted its stake in shares of Mirum Pharmaceuticals by 8.0% during the 3rd quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock valued at $29,546,000 after buying an additional 30,021 shares in the last quarter.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock opened at $103.10 on Monday. The firm has a market cap of $5.30 billion, a PE ratio of -119.88 and a beta of 0.49. The stock has a 50 day moving average of $86.38 and a 200 day moving average of $76.10. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $105.74.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, Director Patrick J. Heron purchased 131,425 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were bought at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the completion of the purchase, the director directly owned 459,010 shares in the company, valued at $31,433,004.80. This trade represents a 40.12% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Eric Bjerkholt sold 1,053 shares of Mirum Pharmaceuticals stock in a transaction on Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $101,288.07. Following the completion of the transaction, the chief financial officer directly owned 43,741 shares of the company’s stock, valued at $4,207,446.79. The trade was a 2.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 45,136 shares of company stock worth $4,352,029. Company insiders own 22.87% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on MIRM shares. Wall Street Zen raised Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. JMP Securities set a $95.00 target price on Mirum Pharmaceuticals in a research report on Wednesday, November 5th. Citizens Jmp boosted their price target on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a report on Friday, December 19th. HC Wainwright upped their price target on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $107.25.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.